FAM161B

Across TCGA pan-cancer cohorts, FAM161B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FAM161B data layer compared with 20 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher FAM161B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM161B expression acts as an unfavorable survival marker.

KIRC and LIHC are the cancer types where FAM161B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.122	0.811	<.001	36	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

FAM161B–KIRC (OS)

Open the KIRC breakdown →